A comparison study of TRx0237 (LMTM) and placebo in patients with early Alzheimer's Disease.
- Conditions
- Alzheimer’s DiseaseMedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2017-003558-17-ES
- Lead Sponsor
- TauRx Therapeutics Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 375
1. Early AD, encompassing probable AD and mild cognitive impairment due to AD (MCI-AD) based on 2011 National Institute on Aging (NIA)/ Alzheimer’s Association (AA) criteria
• All cause dementia and probably AD (probably AD)
In brief, subjects with probable AD dementia must have insidious onset, worsening impairment in at least two cognitive areas (learning and recall, language, executive function, visuospatial skills), sufficient to significantly interfere with work or usual activities, that is not explained by delirium, drugs, major psychiatric disorder, medical illness, cerebrovascular disease, other forms of dementia, or neurological disorder. The accuracy of the diagnosis will be confirmed independently.
OR
•MCI-AD
In subjects with MCI-AD, there should be evidence of concern about a change in cognition, in comparison with the person’s previous level verified by a knowledgeable informant or clinician. There should also be evidence of lower performance in episodic memory than would be expected for the subject’s age and educational background (typically 1 to 1.5 standard deviations below the mean). Other mild cognitive deficits may also be present, but there must be preservation of independence in functional abilities. Subjects should not meet the criteria for dementia. The cognitive changes must be mild and there must be no evidence of a significant impairment in social or occupational functioning. Impairments must not be explained by delirium, drugs, major psychiatric disorder, medical illness, cerebrovascular disease, other forms of dementia, or neurological disorder.
2.Documented PET scan that is positive for amyloid; if most recent PET scan was performed >3 years prior to Screening and was negative, it may be repeated (subjects are not eligible if their most recent PET scan was performed within the 3 years prior to Screening and was negative)
3. MMSE score of 20-27 (inclusive) at Screening
4. Global Clinical Dementia Rating (CDR) score of 0.5 at Screening (including a score of > 0 in one of the functional domains: Community Affairs, Home and Hobbies, or Personal Care) (for both probable AD and MCI-AD)
5. Age < 90 years at Screening
6. Females must meet one of the following:
• Surgically sterile (hysterectomy, bilateral salpingectomy / oophorectomy) for at least 6 months minimum
• Have undergone bilateral tubal occlusion / ligation at least 6 months prior
• Post-menopausal for at least 1 year
• Using adequate contraception (a barrier method [such as condom, diaphragm or cervical/vault cap] with spermicidal foam, gel, film, cream, or suppository; intrauterine device [IUD] or system, or oral or long- acting injected or implanted hormonal contraceptives for at least 90 days prior to Baseline; or vasectomized partner [with the appropriate post-vasectomy documentation of the absence of spermatozoa in the ejaculate]) or true abstinence (when this is in line with the preferred and usual lifestyle of the subject); subjects must be competent to use adequate contraception and to agree to continue to maintain adequate contraception throughout participation in the study (including up to 4 weeks after the last dose of study drug).
7. Subject consistent with national law, is able to re
1. Significant central nervous system (CNS) disorder other than probable Alzheimer’s disease or MCI-AD, e.g., Lewy body dementia, Parkinson’s disease, multiple sclerosis, progressive supranuclear palsy, hydrocephalus, Huntington’s disease, any condition directly or indirectly caused by Transmissible Spongiform Encephalopathy (TSE), CreutzfeldtJakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or new variant Creutzfeldt-Jakob Disease (nvCJD)
2. Significant intracranial focal or vascular pathology seen on brain MRI scan that would, based on the independent reviewer imaging evaluation, lead to a diagnosis other than probable Alzheimer’s disease or MCI-AD, including but not limited to:
•Large confluent white matter hyperintense lesions (i.e., Fazekas score of 3)
•Other focal brain lesions judged clinically relevant by the investigator
•Evidence of a prior or current macrohemorrhage
3. Clinical evidence or history of any of the following (within specified period prior to Baseline):
• Cerebrovascular accident (2 years)
• Transient ischemic attack (6 months)
• Significant head injury with associated loss of consciousness, skull fracture or persisting cognitive impairment (2 years)
• Other unexplained or recurrent loss of consciousness =15 minutes (2 years)
4.Previously diagnosed with epilepsy (a single prior seizure is considered acceptable)
5. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria met (for any of the following within specified period:
• Major depressive disorder (current)
• Schizophrenia (lifetime)
• Other psychotic disorders, bipolar disorder (within the past 5 years)
• Substance (including alcohol) related disorders (within the past 2 years)
6. Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI imaging. MRI compatible prosthetics, clips, stents, or any other device proven to be compatible are allowed
7. Resides in hospital or moderate to high dependency continuous care facility (residence in low grade assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of daily living is allowed so long as it is not mandated by an order issued either by the judicial or the administrative authorities)
8.Any physical disability that would prevent completion of study procedures or assessments (e.g., blindness or significant uncorrected visual impairment, deafness or significant hearing loss not corrected by hearing aids, non AD-related speech impairment)
9. History of swallowing difficulties (note: study drug should be swallowed whole and MUST NOT be broken, crushed, chewed, or dissolved in fluids prior to ingestion)
10. Pregnant or breastfeeding
11. Glucose-6-phosphate dehydrogenase (G6PD) deficiency based on World Health Organization classification (<60% of normal, i.e., <6.1 U/g hemoglobin [Hgb])
12. History of significant hematological abnormality or current acute or chronic clinically significant abnormality, including:
• History of hemoglobinopathy, myelodysplastic syndrome, hemol
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method